WANBURY LIMITED
Latest filings
Next results: Wed, 4 Nov · Financial Results- Board meeting to approve Q2 and half-year results · Results
- Wanbury facilities win safety and employer awards · Business Updates
- Wanbury: USFDA nod for 9 Metformin DMFs, new Saudi and Mexico business · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures active pharmaceutical ingredients (APIs), which account for 88% of FY26 revenue, with a smaller formulations business that reached break-even. Operations are anchored at a manufacturing facility in Tanuku, Andhra Pradesh, which is inspected by overseas regulators including the USFDA and Australia's TGA. The company sells APIs such as Metformin HCl and supplies them to generic drug partners in the US, with drug master files (DMFs) filed in the US and South Korea. New APIs are being added to the portfolio, including an anaesthetic API launched in Q4 FY26, with a stated plan to add four new molecules a year from FY27. Costs are dominated by raw materials at 42% of revenue, followed by employees at 18.4% and other operating expenses at 22.7%. A new 82%-owned Indian subsidiary, Wanbury Skin Health Limited, has been incorporated in the pharma space.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY25 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from WANBURY LIMITED's filed financials and exchange disclosures
What does WANBURY LIMITED do?
WANBURY LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol WANBURY.
Is WANBURY LIMITED profitable?
Yes. Over the trailing twelve months WANBURY LIMITED reported a net profit of ₹43 Cr on revenue of ₹630 Cr.
Does WANBURY LIMITED pay a dividend?
Not in the latest reported year — WANBURY LIMITED's dividend payout for FY25 was nil.
Is WANBURY LIMITED debt-free?
No. It reported borrowings of ₹173 Cr on its 31 Mar 2025 balance sheet, or net debt of ₹169 Cr after cash. Debt stands at 2.92× equity. That is higher than 99% of its 166 Pharmaceuticals peers.
Is WANBURY LIMITED expensive compared with its peers?
On trailing P/E, WANBURY LIMITED ranks 30 of 158 in Pharmaceuticals — cheaper than 82% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the WANBURY LIMITED share price move in a day?
On a typical session WANBURY LIMITED moves 1.81% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.
When are WANBURY LIMITED's next results?
Financial Results on Wed, 4 Nov. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track WANBURY LIMITED's announcements?
Every NSE and BSE filing by WANBURY LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.